Is Veracyte, Inc. overvalued or undervalued?

As of 10 September 2025, the valuation grade for Veracyte, Inc. has moved from attractive to expensive, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 56, an EV to EBITDA of 35.87, and a PEG ratio of 0.12. In comparison, peers such as TransMedics Group, Inc. have a P/E of 50.23 and an EV to EBITDA of 37.01, while Integer Holdings Corp. shows a P/E of 41.17, highlighting that Veracyte's valuation is on the higher end relative to its industry.
Recent stock performance shows that while Veracyte has outperformed the S&P 500 in the short term with a 1-week return of 4.30% compared to 1.05%, it has underperformed year-to-date with a return of -16.09% against the S&P 500's 12.22%. This mixed performance further supports the conclusion that Veracyte, Inc. is currently overvalued.